^
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
ASCO 2022 - 3 days - (New C3)
PD-L1 expression
Gastric Cancer
durvalumab + AZD6738
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 positive
Gastric Cancer
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
KN026
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 expression
Gastric Cancer
KN026
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
VSNL1 underexpression + CD44 underexpression
Gastric Cancer
paclitaxel
Sensitive: B - Late Trials
Sci Rep - 1 week - (New B)
CLDN18.2 positive
Gastric Cancer
CT041
Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
disitamab vedotin
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
cisplatin + capecitabine
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
TCF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FP
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FOLFIRI
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DP
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel + capecitabine
Sensitive: A2 - Guideline
TMB-H
Gastric Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
FLOT
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
docetaxel + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
IP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline